|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral tablet
extended-release tablet
|
|
gptkbp:affiliatedWith
|
antipsychotic medication
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:associatedWith
|
gptkb:risperidone
|
|
gptkbp:ATCCode
|
N05AX13
|
|
gptkbp:brand
|
gptkb:paliperidone
|
|
gptkbp:chemicalFormula
|
C23H27FN4O3
|
|
gptkbp:contraindication
|
hypersensitivity to paliperidone
|
|
gptkbp:developedBy
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
23 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Invega
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Invega_Hafyera
gptkb:Invega_Sustenna
gptkb:Invega_Trinza
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist
|
|
gptkbp:metabolism
|
gptkb:risperidone
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular (as Invega Sustenna)
|
|
gptkbp:sideEffect
|
tremor
weight gain
restlessness
drowsiness
increased prolactin
|
|
gptkbp:usedFor
|
gptkb:schizoaffective_disorder
schizophrenia
|
|
gptkbp:bfsParent
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|